Status:
COMPLETED
An Open-labeled Trial of Ramipril in Patients With Migraine
Lead Sponsor:
Seoul National University Hospital
Conditions:
Migraine With Hypertension
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
Brief Summary
Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy...
Eligibility Criteria
Inclusion
- Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.
Exclusion
- Medication overuse headache are excluded in this study.
- Treatment with other ACEI or medication that may affect ARS
- Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
- Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01402479
Start Date
October 1 2004
End Date
July 1 2005
Last Update
August 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744